WO2012107765A3 - Formulation de particules - Google Patents

Formulation de particules Download PDF

Info

Publication number
WO2012107765A3
WO2012107765A3 PCT/GB2012/050283 GB2012050283W WO2012107765A3 WO 2012107765 A3 WO2012107765 A3 WO 2012107765A3 GB 2012050283 W GB2012050283 W GB 2012050283W WO 2012107765 A3 WO2012107765 A3 WO 2012107765A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmacologically active
active ingredients
particle
particle formulations
formulation
Prior art date
Application number
PCT/GB2012/050283
Other languages
English (en)
Other versions
WO2012107765A2 (fr
Inventor
Mark Henry SAUNDERS
Marcel De Matas
Jason Robert Jones
Original Assignee
Kuecept Ltd
Lena Nanoceutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuecept Ltd, Lena Nanoceutics Ltd filed Critical Kuecept Ltd
Publication of WO2012107765A2 publication Critical patent/WO2012107765A2/fr
Publication of WO2012107765A3 publication Critical patent/WO2012107765A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des formulations de particules combinées, appropriées pour être utilisées dans une formulation d'inhalateur comprenant plusieurs ingrédients pharmacologiquement actifs caractérisés en ce que les ingrédients pharmacologiquement actifs sont cristallins. La présente invention comprend en outre une formulation de particules appropriée pour être utilisée dans une formulation d'inhalation comprenant plusieurs ingrédients pharmacologiquement actifs, par exemple des ingrédients pharmacologiquement actifs cristallins caractérisés en ce que le rapport des substances pharmacologiquement actives présente une distribution de moins de ±5 % du rapport cible tel que mesuré par un test d'impacteur. En particulier, la présente invention porte sur des formulations de particules préparées à partir de nanoparticules, par exemple par séchage par pulvérisation d'une suspension aqueuse de nanoparticules. L'invention comprend en outre des procédés de fabrication desdites formulations de particules et un procédé d'utilisation desdites formulations de particules dans des traitements thérapeutiques pour parvenir à une co-localisation d'agents dans le corps, en particulier lorsqu'elles sont administrées sous la forme de formulations inhalées aux voies aériennes et aux poumons d'êtres humains.
PCT/GB2012/050283 2011-02-09 2012-02-09 Formulation de particules WO2012107765A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1102237.3 2011-02-09
GBGB1102237.3A GB201102237D0 (en) 2011-02-09 2011-02-09 Particle formulation

Publications (2)

Publication Number Publication Date
WO2012107765A2 WO2012107765A2 (fr) 2012-08-16
WO2012107765A3 true WO2012107765A3 (fr) 2012-11-15

Family

ID=43836446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/050283 WO2012107765A2 (fr) 2011-02-09 2012-02-09 Formulation de particules

Country Status (2)

Country Link
GB (1) GB201102237D0 (fr)
WO (1) WO2012107765A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663117C2 (ru) 2012-05-08 2018-08-01 Никокс Офтэлмикс, Инк. Препараты гидрофобных терапевтических средств, способы их получения и применения
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
EP3107548B8 (fr) 2014-02-20 2022-07-20 Otitopic Inc. Préparations de poudre sèche à inhaler
WO2016019253A1 (fr) 2014-07-31 2016-02-04 Otitopic Inc. Formulations de poudre sèche à inhaler
AU2015330010A1 (en) * 2014-10-08 2017-04-27 Zambon S.P.A. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
DE102016218604A1 (de) 2016-09-27 2018-03-29 Constantin Adams Partikuläres Stoffgemisch, vorzugsweise zur Verwendung bei der Prophylaxe und/oder Behandlung einer Atemwegsstörung
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2021216710A1 (fr) * 2020-04-24 2021-10-28 The Medical College Of Wisconsin, Inc. Utilisation du salmétérol en tant qu'agent antiviral

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254127A1 (en) * 2000-10-06 2008-10-16 Orion Corporation Inhalation particles incorporating a combination of two or more active ingredients
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL175564B1 (pl) 1993-10-01 1999-01-29 Astra Ab Sposób i urządzenie do formowania leku w proszku oraz lek w proszku
US7572430B2 (en) 2000-11-09 2009-08-11 Cyprus Amax Minerals Company Method for producing nano-particles
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
EP2083944A4 (fr) 2006-10-24 2013-07-24 Beneq Oy Dispositif de production de nanoparticules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20080254127A1 (en) * 2000-10-06 2008-10-16 Orion Corporation Inhalation particles incorporating a combination of two or more active ingredients
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHIKO KUMON ET AL: "Can low-dose combination products for inhalation be formulated in single crystalline particles?", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 40, no. 1, 1 April 2010 (2010-04-01), pages 16 - 24, XP055036842, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2010.02.004 *
REINHARD VEHRING: "Pharmaceutical Particle Engineering via Spray Drying", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 25, no. 5, 28 November 2007 (2007-11-28), pages 999 - 1022, XP019613056, ISSN: 1573-904X *

Also Published As

Publication number Publication date
WO2012107765A2 (fr) 2012-08-16
GB201102237D0 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
WO2012107765A3 (fr) Formulation de particules
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
JP2013224331A5 (fr)
WO2008084312A3 (fr) Particules micronisées d'agents actifs à faible puissance posologique pour des formulations en poudre pour inhalation
NO20064161L (no) Farmasoytiske formuleringer for torrpulverinhalatorer omfattende en aktiv ingrediens med lavdoseringsstyrke
WO2012016889A3 (fr) Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase
UA101653C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
JOP20120023B1 (ar) صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
HRP20151214T1 (hr) Pripravak za inhalaciju koji sadrži aklidinij za lijeäśenje kroniäśne opstruktivne pluä†ne bolesti
WO2014016548A3 (fr) Composition pharmaceutique
JP2014528470A5 (fr)
WO2014153160A3 (fr) Procédé d'amélioration des propriétés de biorépartition et de ciblage de tissu de particules ceo2 thérapeutiques via la nano-encapsulation et l'enrobage
BR112014008602A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
WO2012040228A3 (fr) Composition d'aérosol destinée à administrer des médicaments
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
PH12014502746A1 (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
JP2015519356A5 (fr)
MD20140131A2 (ro) Doză şi formă preparativă nouă pentru inhalare care cuprinde aclidiniu
MY179794A (en) Compound composition for inhalation used for treating asthma
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
JP2011500731A5 (fr)
HRP20221034T1 (hr) Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća
JP2013522295A5 (fr)
WO2011093812A3 (fr) Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12706097

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12706097

Country of ref document: EP

Kind code of ref document: A2